Cilostazol

Generic Name: Cilostazol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Associated Therapies: -

Clinical Trials

Cilostazol in Parkinson's Disease

Phase 2

Not yet recruiting

Conditions: Parkinson's Disease

Interventions: Drug: Cilostazol
Drug: Placebo
Drug: Standard treatment

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 50

Registration Number: NCT06612593

Locations: 🇪🇬
Ain Shams University Hospital, Cairo, Egypt

Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Phase 3

Recruiting

Conditions: Cerebral Microbleeds
Stroke

Interventions: Drug: Cilostazol
Drug: Aspirin

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Zhejiang Provincial People's Hospital

Target Recruit Count: 848

Registration Number: NCT06530537

Locations: 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Cilostazol and Aspirin in Stroke and TIA

Phase 4

Completed

Conditions: TIA
Ischemic Stroke

Interventions: Drug: Clopidogrel
Drug: Cilostazol

First Posted Date: 2024-07-26

Last Posted Date: 2024-08-06

Lead Sponsor: Incheon St.Mary's Hospital

Target Recruit Count: 378

Registration Number: NCT06522113

Locations: 🇰🇷
The Catholic university of korea, Incheon St. Mary's hospital, Incheon, Korea, Republic of

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Phase 2

Recruiting

Conditions: Fallopian Tube Carcinoma
Malignant Solid Neoplasm
Malignant Uterine Neoplasm
Vulvar Carcinoma
Cervical Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Device: Cryocompression Therapy
Other: Best Practice
Drug: Cilostazol
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2024-07-09

Last Posted Date: 2024-08-15

Lead Sponsor: Emory University

Target Recruit Count: 70

Registration Number: NCT06492070

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Clopidogrel Versus Cilostazol on Vessels

Phase 4

Recruiting

Conditions: Type 2 Diabetes
Atherosclerosis

Interventions: Drug: Clopidogrel
Drug: Cilostazol

First Posted Date: 2024-05-07

Last Posted Date: 2024-05-07

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 120

Registration Number: NCT06402747

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients

Phase 2

Recruiting

Conditions: Wound Heal

Interventions: Drug: Cilostazol
Drug: Selenium

First Posted Date: 2023-11-07

Last Posted Date: 2023-11-07

Lead Sponsor: Ain Shams University

Target Recruit Count: 200

Registration Number: NCT06117436

Locations: 🇪🇬
National Institute of Diabetes and Endocrinology, Cairo, Egypt

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

Active, not recruiting

Conditions: Peripheral Artery Disease

Interventions: Drug: Cilostazol
Drug: Pentoxifylline

First Posted Date: 2022-12-02

Last Posted Date: 2023-07-19

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 10398

Registration Number: NCT05635370

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache

Not Applicable

Recruiting

Conditions: Post-Traumatic Headache

Interventions: Drug: Placebo
Drug: Cilostazol

First Posted Date: 2022-10-27

Last Posted Date: 2023-02-08

Lead Sponsor: Danish Headache Center

Target Recruit Count: 21

Registration Number: NCT05595993

Locations: 🇩🇰
Danish Headache Center, Copenhagen, Denmark

Cilostazol and Methotrexate in Rheumatoid Arthritis

Phase 3

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Cilostazol
Drug: Placebo
Drug: Methotrexate

First Posted Date: 2022-10-26

Last Posted Date: 2024-04-10

Lead Sponsor: Tanta University

Target Recruit Count: 70

Registration Number: NCT05594680

Locations: 🇪🇬
Faculty of medicine, Mansoura, Egypt

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Phase 1

Completed

Conditions: Peripheral Neuropathy
Breast Cancer

Interventions: Drug: Cilostazol
Drug: Placebo

First Posted Date: 2022-03-28

Last Posted Date: 2023-03-15

Lead Sponsor: Mansoura University

Target Recruit Count: 71

Registration Number: NCT05298696

Locations: 🇪🇬
Mansoura University, Mansoura, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy